GT Medical Technologies Reaches Two Clinical Milestones with GammaTile® for Brain Tumor Treatment

GT Medical Technologies, Inc. (GT MedTech), a company dedicated to enhancing the treatment of brain tumor patients, has announced significant clinical progress in the use of its GammaTile® therapy. The company recently celebrated the implantation of its 1,500th GammaTile and the enrollment of the 400th patient in a multi-center registry study aimed at further validating this innovative treatment.

GammaTile is a unique bioabsorbable collagen implant embedded with Cesium-131 seeds, designed to deliver targeted radiation therapy immediately after brain tumor removal. This approach aims to eliminate residual cancer cells while minimizing radiation exposure to healthy brain tissue. The 1,500th GammaTile implant took place at Brooke Army Medical Center in Fort Sam Houston, Texas, performed by neurosurgeon Dr. Ryan Morton on a patient with recurrent glioblastoma.

Dr. Morton emphasized that this milestone underscores the progress being made in providing cutting-edge care to brain tumor patients across the country. He noted the ease of use and clinical effectiveness of GammaTile, expressing pride in offering this advanced therapy at Brooke Army Medical Center.

The multi-center registry study (NCT04427384) enrolled its 400th patient at Henry Ford Health in Detroit, Michigan. Dr. Adam Robin, a neurosurgeon and co-director of the CNS Metastatic Program at Henry Ford Health, treated the milestone patient. Dr. Robin highlighted the critical role GammaTile plays for patients who may have limited treatment options, expressing pride in contributing to the growing clinical data supporting brain brachytherapy.

The registry study aims to collect comprehensive follow-up data over five years, including local tumor control, overall survival rates, quality of life assessments, functional status, and potential adverse events related to surgery and radiation. This data will be instrumental in demonstrating the long-term benefits and safety of GammaTile, potentially establishing it as a preferred treatment option for patients with operable brain tumors.

Michael Garcia, MD, MS, Chief Medical Officer and Head of Clinical Development at GT MedTech, pointed out that multiple independent healthcare institutions across the country have published positive findings on the use of GammaTile for treating various brain tumors, such as brain metastases, glioblastoma, and meningioma. These reports consistently show excellent efficacy and safety profiles, encouraging wider adoption of GammaTile among physicians nationwide.

GT Medical Technologies was founded by a team of brain tumor specialists committed to raising the standard of care for brain tumor patients. GammaTile received FDA clearance for treating newly diagnosed and recurrent malignant intracranial neoplasms. Since its market release in the United States in March 2020, GammaTile has been adopted by over 100 leading medical institutions, with more centers incorporating this therapy each month.

In addition to its clinical advancements, GT MedTech remains focused on expanding the accessibility of GammaTile to ensure more patients can benefit from this revolutionary therapy. The company's ongoing efforts to gather and analyze clinical data will continue to support the broader adoption of GammaTile as an effective treatment for brain tumors.

GT Medical Technologies' commitment to improving patient outcomes and advancing brain tumor treatment options is evident through its achievements and dedication to clinical research. The company's milestones in GammaTile implantation and registry enrollment represent significant steps forward in the fight against brain tumors, offering hope and new treatment possibilities to patients nationwide.